therapeutic prostate cancer peptide vaccine TENDU

{
  "id": "MLC-T-ONC-017135",
  "term": "therapeutic prostate cancer peptide vaccine TENDU",
  "field": "Oncology and biomedicine",
  "definition": "A peptide cancer vaccine, based on the tetanus-epitope targeting (TET)-platform, composed of as of yet undisclosed tumor-associated antigens (TAAs) that are specific for prostate cancer and a tetanus-based vaccine adjuvant in the same molecule, with potential immunomodulating and antineoplastic activities. Upon administration, therapeutic prostate cancer peptide vaccine TENDU may stimulate a potent cytotoxic T-lymphocyte (CTL) immune response against prostate cancer cells that express these TAAs, resulting in tumor cell lysis. The tetanus peptide may enhance the anti-tumor immune response.",
  "synonyms": [
    "TENDU vaccine",
    "TENDU",
    "tetanus-epitope-targeting-based prostate cancer peptide vaccine TENDU",
    "TET-based prostate cancer peptide vaccine TENDU"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/therapeutic-prostate-cancer-peptide-vaccine-tendu/"
}